| Title: |
Minimal Residual Disease-Guided Combination of Ibrutinib and Venetoclax Compared to FCR in Untreated Patients with CLL of Intermediate Risk : Interim Results of MRD Kinetics in the Eradic Trial from the Filo Group |
| Authors: |
Michallet, Anne-Sophie, Quinquenel, Anne, Letestu, Remi, Magali, Tavernier, Morisset, Stéphane, Aurran, Therese, Laribi, Kamel, Cymbalista, Florence, Levy, Vincent, Simon, Laurence, Roos Weil, Damien, Leblond, Veronique, Dilhuydy, Marie Sarah, Tomowiak, Cecile, Dartigeas, Caroline, Guieze, Romain, Tournilhac, Olivier, Ferrant, Emmanuelle, De Guibert, Sophie, Feugier, Pierre, Merabet, Fatiha, Lepretre, Stéphane, Carassou, Philippe, Gay, Julie, Hivert, Benedicte, Fornecker, Luc Matthieu, Dupuis, Jehan, Molina, Lysiane, Villemagne, Bruno, Cartron, Guillaume, Drenou, Bernard, Mahé, Béatrice, Benbrahim, Omar, Cahu, Xavier, Portois, Christelle, Ysebaert, Loic, Nguyen Khac, Florence, Rouillé, Valerie, Delmer, Alain Jacques |
| Source: |
In Blood 2 November 2023 142 Supplement 1:3268-3268 |
| Database: |
ScienceDirect |
